Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Medtech Insight

Generics Bulletin

Generics Firms On Standby With Tecfidera Appeal Due ‘At Any Time’

Implication Of Potential Pro-Biogen Ruling Unclear

Apr 23 2021

• By Dean Rudge

Biogen_Switzerland — first-quarter 2021 sales of Tecfidera nosedived by 79% • Source: Shutterstock

Related Content

Sandoz Among Winners As US Court Applies Tecfidera Patent Invalidity Ruling

Sep 17 2020

Biogen Sees At Least Six Tecfidera Generics And 90% Discounts

Oct 22 2020

A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen

Apr 19 2021

Related Companies

Biogen, Inc.

Additional Topics

United States Generic Drugs Legal Issues Intellectual Property Neurology BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and Conditions Opens in new window

Privacy PolicyOpens in new window